In re Xyrem (Sodium Oxybate) Antitrust Litigation

  1. August 28, 2024

    Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

    Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under a newly unsealed California federal court order largely rejecting competing motions for summary judgment.

  2. July 19, 2024

    Jazz Says Narcolepsy Drug Charge MDL Should Be Tossed

    Jazz Pharmaceuticals urged a California federal judge to toss claims from insurers and consumers pursuing multidistrict litigation accusing the drugmaker of staving off generic competition to its blockbuster narcolepsy medicine Xyrem through antitrust conduct and deals with other drugmakers, saying the company engaged in "permissible competition."

  3. November 16, 2023

    Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit

    Illinois is looking for a way back into an ongoing class action against Jazz Pharmaceuticals, telling the California federal judge presiding over the multidistrict case that another judge's order excluding Illinois insurers who reimbursed patients for the price of narcolepsy drug Xyrem should be reversed.

  4. May 16, 2023

    Jazz Ducks BCBS Claims But Not Xyrem Class Cert.

    A California federal judge granted class certification Friday to insurers and consumers pursuing multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anti-competitive conduct and deals with other drugmakers, even as he nixed Blue Cross Blue Shield claims.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!